These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 29341334)

  • 1. Incidence and prognostic impact of cytogenetic aberrations in patients with systemic mastocytosis.
    Naumann N; Jawhar M; Schwaab J; Kluger S; Lübke J; Metzgeroth G; Popp HD; Khaled N; Horny HP; Sotlar K; Valent P; Haferlach C; Göhring G; Schlegelberger B; Meggendorfer M; Hofmann WK; Cross NCP; Reiter A; Fabarius A
    Genes Chromosomes Cancer; 2018 May; 57(5):252-259. PubMed ID: 29341334
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cytogenetic abnormalities in systemic mastocytosis: WHO subcategory-specific incidence and prognostic impact among 348 informative cases.
    Shah S; Pardanani A; Elala YC; Lasho TL; Patnaik MM; Reichard KK; Hanson CA; Ketterling RP; Tefferi A
    Am J Hematol; 2018 Dec; 93(12):1461-1466. PubMed ID: 30152525
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cytogenetic and molecular aberrations and worse outcome for male patients in systemic mastocytosis.
    Kluin-Nelemans HC; Jawhar M; Reiter A; van Anrooij B; Gotlib J; Hartmann K; Illerhaus A; Oude Elberink HNG; Gorska A; Niedoszytko M; Lange M; Scaffidi L; Zanotti R; Bonadonna P; Perkins C; Elena C; Malcovati L; Shoumariyeh K; von Bubnoff N; Müller S; Triggiani M; Parente R; Schwaab J; Kundi M; Fortina AB; Caroppo F; Brockow K; Zink A; Fuchs D; Angelova-Fischer I; Yavuz AS; Doubek M; Mattsson M; Hagglund H; Panse J; Simonowski A; Sabato V; Schug T; Jentzsch M; Breynaert C; Várkonyi J; Kennedy V; Hermine O; Rossignol J; Arock M; Valent P; Sperr WR
    Theranostics; 2021; 11(1):292-303. PubMed ID: 33391475
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Additional mutations in SRSF2, ASXL1 and/or RUNX1 identify a high-risk group of patients with KIT D816V(+) advanced systemic mastocytosis.
    Jawhar M; Schwaab J; Schnittger S; Meggendorfer M; Pfirrmann M; Sotlar K; Horny HP; Metzgeroth G; Kluger S; Naumann N; Haferlach C; Haferlach T; Valent P; Hofmann WK; Fabarius A; Cross NC; Reiter A
    Leukemia; 2016 Jan; 30(1):136-43. PubMed ID: 26464169
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular profiling of myeloid progenitor cells in multi-mutated advanced systemic mastocytosis identifies KIT D816V as a distinct and late event.
    Jawhar M; Schwaab J; Schnittger S; Sotlar K; Horny HP; Metzgeroth G; Müller N; Schneider S; Naumann N; Walz C; Haferlach T; Valent P; Hofmann WK; Cross NC; Fabarius A; Reiter A
    Leukemia; 2015 May; 29(5):1115-22. PubMed ID: 25567135
    [TBL] [Abstract][Full Text] [Related]  

  • 6. KIT D816 mutated/CBF-negative acute myeloid leukemia: a poor-risk subtype associated with systemic mastocytosis.
    Jawhar M; Döhner K; Kreil S; Schwaab J; Shoumariyeh K; Meggendorfer M; Span LLF; Fuhrmann S; Naumann N; Horny HP; Sotlar K; Kubuschok B; von Bubnoff N; Spiekermann K; Heuser M; Metzgeroth G; Fabarius A; Klein S; Hofmann WK; Kluin-Nelemans HC; Haferlach T; Döhner H; Cross NCP; Sperr WR; Valent P; Reiter A
    Leukemia; 2019 May; 33(5):1124-1134. PubMed ID: 30635631
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical and histopathological features of myeloid neoplasms with concurrent Janus kinase 2 (JAK2) V617F and KIT proto-oncogene, receptor tyrosine kinase (KIT) D816V mutations.
    Naumann N; Lübke J; Shomali W; Reiter L; Horny HP; Jawhar M; Dangelo V; Fabarius A; Metzgeroth G; Kreil S; Sotlar K; Oni C; Harrison C; Hofmann WK; Cross NCP; Valent P; Radia D; Gotlib J; Reiter A; Schwaab J
    Br J Haematol; 2021 Jul; 194(2):344-354. PubMed ID: 34060083
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical impact and proposed application of molecular markers, genetic variants, and cytogenetic analysis in mast cell neoplasms: Status 2022.
    Arock M; Hoermann G; Sotlar K; Hermine O; Sperr WR; Hartmann K; Brockow K; Akin C; Triggiani M; Broesby-Olsen S; Reiter A; Gotlib J; Horny HP; Orfao A; Metcalfe DD; Valent P
    J Allergy Clin Immunol; 2022 Jun; 149(6):1855-1865. PubMed ID: 35430191
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The KIT D816V expressed allele burden for diagnosis and disease monitoring of systemic mastocytosis.
    Erben P; Schwaab J; Metzgeroth G; Horny HP; Jawhar M; Sotlar K; Fabarius A; Teichmann M; Schneider S; Ernst T; Müller MC; Giehl M; Marx A; Hartmann K; Hochhaus A; Hofmann WK; Cross NC; Reiter A
    Ann Hematol; 2014 Jan; 93(1):81-8. PubMed ID: 24281161
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comprehensive mutational profiling in advanced systemic mastocytosis.
    Schwaab J; Schnittger S; Sotlar K; Walz C; Fabarius A; Pfirrmann M; Kohlmann A; Grossmann V; Meggendorfer M; Horny HP; Valent P; Jawhar M; Teichmann M; Metzgeroth G; Erben P; Ernst T; Hochhaus A; Haferlach T; Hofmann WK; Cross NC; Reiter A
    Blood; 2013 Oct; 122(14):2460-6. PubMed ID: 23958953
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Next-generation sequencing in systemic mastocytosis: Derivation of a mutation-augmented clinical prognostic model for survival.
    Pardanani A; Lasho T; Elala Y; Wassie E; Finke C; Reichard KK; Chen D; Hanson CA; Ketterling RP; Tefferi A
    Am J Hematol; 2016 Sep; 91(9):888-93. PubMed ID: 27214377
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ASXL1 but not TET2 mutations adversely impact overall survival of patients suffering systemic mastocytosis with associated clonal hematologic non-mast-cell diseases.
    Damaj G; Joris M; Chandesris O; Hanssens K; Soucie E; Canioni D; Kolb B; Durieu I; Gyan E; Livideanu C; Chèze S; Diouf M; Garidi R; Georgin-Lavialle S; Asnafi V; Lhermitte L; Lavigne C; Launay D; Arock M; Lortholary O; Dubreuil P; Hermine O
    PLoS One; 2014; 9(1):e85362. PubMed ID: 24465546
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Systemic Mastocytosis: Advances in Diagnosis and Current Management.
    Pullarkat ST; Wu W; Pullarkat V
    Cancer Treat Res; 2021; 181():167-178. PubMed ID: 34626361
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical and Molecular Diagnostic Evaluation of Systemic Mastocytosis in the South-Eastern Hungarian Population Between 2001-2013--A Single Centre Experience.
    Marton I; Krenács L; Bagdi E; Bakos A; Demeter J; Borbényi Z
    Pathol Oncol Res; 2016 Apr; 22(2):293-9. PubMed ID: 26545382
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adverse Prognostic Impact of the
    Naumann N; Lübke J; Baumann S; Schwaab J; Hoffmann O; Kreil S; Dangelo V; Reiter L; Bugert P; Kristensen T; Sotlar K; Haselmann V; Schneider S; Metzgeroth G; Weiss C; Popp HD; Fabarius A; Hofmann WK; Cross NCP; Reiter A; Jawhar M
    Int J Mol Sci; 2021 Mar; 22(5):. PubMed ID: 33806359
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Systemic mastocytosis in adults: 2021 Update on diagnosis, risk stratification and management.
    Pardanani A
    Am J Hematol; 2021 Apr; 96(4):508-525. PubMed ID: 33524167
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Systemic mastocytosis in adults: 2019 update on diagnosis, risk stratification and management.
    Pardanani A
    Am J Hematol; 2019 Mar; 94(3):363-377. PubMed ID: 30536695
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Variable presence of KITD816V in clonal haematological non-mast cell lineage diseases associated with systemic mastocytosis (SM-AHNMD).
    Sotlar K; Colak S; Bache A; Berezowska S; Krokowski M; Bültmann B; Valent P; Horny HP
    J Pathol; 2010 Apr; 220(5):586-95. PubMed ID: 20112369
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diagnosis and management of mastocytosis: an emerging challenge in applied hematology.
    Valent P
    Hematology Am Soc Hematol Educ Program; 2015; 2015():98-105. PubMed ID: 26637707
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Frequency and prognostic impact of
    Muñoz-González JI; Álvarez-Twose I; Jara-Acevedo M; Henriques A; Viñas E; Prieto C; Sánchez-Muñoz L; Caldas C; Mayado A; Matito A; Dasilva-Freire N; Orfao A; García-Montero AC
    Blood; 2019 Aug; 134(5):456-468. PubMed ID: 31151985
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.